Eli Lilly specializes in obesity and diabetes treatments, among other areas. It's reasonable to expect a lot more growth from ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

When Eli Lilly (LLY) posted strong quarterly results, the stock fell from $750 to $625.65 by August 8. Shareholders fretted about clinical results from its next-generation obesity drug. Its 37.7% Y/Y ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q2 CY2025 results exceeding the market’s revenue expectations, ...

The Government has joined forces with the pharmaceutical giant that makes weight loss jab Mounjaro in a bid to tackle obesity ...

Eli Lilly and Company (NYSE:LLY) revealed the topline results of the SURPASS-CVOT Phase 3 trial, which showed that Mounjaro ...

Shares of Eli Lilly (NYSE: LLY), the pharmaceuticals giant and maker of the Mounjaro and Zepbound weight loss drugs, saw its ...

A wide variety of unapproved FDA drugs were discovered during inspections, including nearly 55,000 fake injectables and pills ...